| August 3 |
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy |
| August 3 |
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA |
| August 3 |
ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer |
| August 3 |
SuperGen's MP-470 Demonstrates Clinical Benefit in Small Cell Lung Cancer and Neuroendocrine Tumor Patients |
| August 3 |
Results from a Phase 2 Study of ABRAXANE In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer |
| August 4 |
Int'l Swine Flu Conference Add More Breakout Sessions |
| August 4 |
Technology Vision Group Presents BioPartnering Europe's Extensive and Topical Conference Program |
| August 4 |
TAXI "Driver" Lavoie Headed to the CTAM Summit |
| August 4 |
Advaxis Executive VP of Science and Operations Dr. John Rothman to Present at the 2009 Immunotherapeutics & Vaccine Summit (IMVACS) |
| August 4 |
VivaGel Demonstrates Anti-HIV and Herpes Activity Following Human Administration |
| August 4 |
Merck KGaA Presented New Data On the Combination of Erbitux with Standard First-Line Therapy in Patients with NSCLC |
| August 4 |
Novel Chemotherapy Agent Bendamustine Significantly More Effective First-Line Therapy than Chlorambucil in CLL |
| August 5 |
First Human Demonstration of Significant, Persistent Antibody Response Using Electroporation-Delivered DNA Vaccine Published in Human Gene Therapy |
| August 5 |
Phase Forward to Present at the 11th Annual Pacific Crest Technology Leadership Forum |
| August 5 |
Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting |
| August 5 |
Clinical Data Evaluating Amrubicin as Potential Therapy for Patients with Small Cell Lung Cancer Presented at 13th World Conference on Lung Cancer |
| August 5 |
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia |
| August 5 |
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis |
| August 5 |
RXi Pharmaceuticals Presented Data from Animal Trials Demonstrating the Utility of Self-Delivering RNAi at IBC's Oligonucleotide Therapeutics Conference |
| August 5 |
GeoVax Labs, Inc. Provides Clinical Studies Update |
| August 5 |
M. D. Anderson Study Finds Common Diabetic Therapy Reduces Risk of Pancreatic Cancer |
| August 5 |
Heartbeat's Bill Drummy Will Be Featured at HBA -- The Beauty Event in New York City |
| August 5 |
The Group Room to Broadcast Live from the 13th World Conference on Lung Cancer |
| August 5 |
Data Demonstrate New Imiquimod Formulation as Short Course Treatment for Actinic Keratosis |
| August 5 |
MIXX 2009 To Showcase Powerful Roster of the Best Minds Fueling Interactive's Creative Revolution |
| August 5 |
FDA Accepts NDA for New Imiquimod Product |
| August 6 |
Scientific Article Outlines Role of Galectin-3 in Heart Failure Development and Progression |
| August 6 |
Med Ad News? PharmaMed Marketing & Media Conference Announces Updates to the Three Innovative Sales-Force-Effectiveness, Digital Marketing & Patient Centered Communication Tracks |
| August 6 |
Galapagos NV (BE) - Galapagos successfully completes first Phase I study for GLPG0259 |
| August 6 |
Opaxio Combined with Alimta Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer |
| August 6 |
Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference |
| August 6 |
Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer |
| August 6 |
Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome |
| August 6 |
Journal of Clinical Oncology Publishes TREANDA Study Demonstrating Significant Improvement in Overall Response and Progression-Free Survival in Chronic Lymphocytic Leukemia |
| August 6 |
Alzheimer's Disease is the Focus of TBSI Annual Neuroscience Symposium |
| August 6 |
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R) |
| August 7 |
Bionovo Presents Positive Results from Phase 1B Trial of Bezielle for Metastatic Breast Cancer |
| August 7 |
Nanotherapeutics Announces NanoBUP Capsule for Treating Opiate Addiction Demonstrated Bioavailability and Safety in Phase Ia Clinical Trial |
| August 10 |
NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99% |
| August 10 |
Human Swine Flu Conference to be Held in Washington DC Next Week |
| August 10 |
Positive Top Line Results from Phase III Study (MARVEL) of anti-influenza Virus Agent 'CS-8958' |
| August 10 |
Depomed Reports Encouraging Results of its Phase I Trial for DM-1992 Program in Parkinson's Disease |
| August 10 |
Vectibix in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer |
| August 11 |
Knopp Neurosciences to Present Phase 2 Results of KNS-760704 in ALS |
| August 11 |
AVANIR Announces Positive Phase III Study Results for Zenvia |
| August 11 |
Array BioPharma Reports Positive Results of Its Oral Glucokinase Activator in Type 2 Diabetes Patients |
| August 11 |
Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody |
| August 11 |
Javelin Pharmaceuticals Reports Ereska (Intranasal Ketamine) Phase III Trial Results in Postoperative Orthopedic Pain |
| August 11 |
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss |
| August 11 |
AVANIR Pharmaceuticals Schedules Conference Call to Discuss Phase III Results for Zenvia in Pseudobulbar Affect |
| August 11 |
As Aging Populations Rise, World-Renowned Aging Experts Will Convene to Share Insights into How to Achieve a Healthy Lifespan |
| August 11 |
Pluristem Therapeutics Will Present the Phase I Study for PLX-PAD in Critical Limb Ischemia at MSC2009 Regenerative Medicine and Adult Stem Cell Therapy Conference |
| August 11 |
Endocyte Announces Positive Results from a Phase II Clinical Study of EC145 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) |
| August 11 |
Romaco at PackExpo in Las Vegas |
| August 12 |
NanoViricides, Inc. Herpes Study Results Discussed on CBS News Report |
| August 12 |
Endocyte announces positive results from a Phase II clinical study of EC145 in patients with advanced non-small cell lung cancer (NSCLC) |
| August 12 |
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration |
| August 12 |
ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients |
| August 12 |
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery |
| August 12 |
Accera Announces Peer-Reviewed Publication of the Results of its 90-Day Clinical Study of AC-1202 (Axona ) in Mild to Moderate Alzheimer's Disease |
| August 12 |
CytRx's Drug Candidate INNO-206 Produces Statistically Significant Tumor Shrinkage in Animal Model of Small Cell Lung Cancer |
| August 12 |
Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration |
| August 12 |
NuPathe Reports Positive Phase III Results for Zelrix, a Novel Transdermal Patch for Acute Migraine |
| August 13 |
BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program |
| August 13 |
Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application for the Oral Delivery of Cobra Venom for the Treatment of Pain |
| August 14 |
Tranzyme Pharma to Present at American Chemical Society (ACS) 2009 National Meeting |
| August 14 |
Risk of suicidal behaviour with antidepressants strongly linked to age |
| August 14 |
No clear evidence that antivirals prevent complications in children with seasonal flu |
| August 14 |
BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Program |
| August 14 |
Kuros Announces Encouraging Phase IIa Data with KUR-212 in Patients with Burns Requiring Mesh Grafting |
| August 14 |
Genmab Announces Preliminary Top-Line Results for Arzerra in Front Line CLL |
| August 14 |
Metabolomics Aids in Understanding Mechanisms of Commonly Used Drugs |
| August 14 |
Cannabis Science Reports On Two Cannabis-Based Drug Release Programs |
| August 17 |
Human Genome Achieves Lupus Drug Goals With DSG's EDC |
| August 17 |
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia |
| August 18 |
BioSante Pharmaceuticals Reports 100% Protection From H1N1 Challenge When Using BioVant Adjuvanted Vaccine |
| August 18 |
NanoBio to Present Preclinical Data on its Novel, Nanoemulsion-based Vaccine Adjuvant Platform at the Immunotherapeutics & Vaccine Summit |
| August 18 |
Vectibix Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer |
| August 18 |
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer |
| August 18 |
GlaxoSmithKline and Genmab Announce Results from a Study of Arzerra in Rituximab Refractory Follicular NHL |
| August 18 |
Sinovac Reports Top-Line Preliminary Results of H1N1 Vaccine Clinical Trials |
| August 18 |
New Study Reinforces Safety Profile of Gardasil, the Cervical Cancer Vaccine |
| August 19 |
Forest Announces Phase IIb Study Results For Oglemilast in Chronic Obstructive Pulmonary Disease |
| August 19 |
PCI Biotech Holding (NO) - Anti-tumour drug more potent with light-directed delivery |
| August 19 |
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease |
| August 19 |
Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis |
| August 19 |
Novavax Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus |
| August 19 |
Lilly Reports on Outcome of Phase III Study of Arzoxifene |
| August 19 |
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease |
| August 19 |
Study Examines Adverse Events Associated With Human Papillomavirus Vaccine |
| August 19 |
Ablynx Announces Positive Phase I Results for Subcutaneous Administration of it's Ant-thrombotic NanobodyR (ALX-0681) |
| August 20 |
Results In The New England Journal Of Medicine Confirm Novartis Drug Femara Is Superior to Tamoxifen After Breast Cancer Surgery |
| August 20 |
Study published in the NEJM shows that oral Iressa (gefitinib) Provides Superior Efficacy Compared To Doublet Chemotherapy In Phase III First-Line Study In Non Small Cell Lung Cancer |
| August 20 |
Study shows pain is "intolerable" for over a third of cancer patients, but nearly three quarters are battling the burden of side effects as a result of their pain treatment |
| August 20 |
PCF Funding for Bone Metastasis Research Supports New Drug to Improve Lives of Prostate Cancer Patients |
| August 20 |
Anti-Tumour Drug More Potent With Light-Directed Delivery |
| August 21 |
NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting |
| August 24 |
Resolvyx Announces Positive Data from Phase 2 Clinical Trial of the Resolvin RX-10045 in Patients with Dry Eye Syndrome |
| August 25 |
CytRx's Arimoclomol Demonstrates Statistically Significant Cellular Evidence of Both Neuroprotection and Neuroregeneration in Animal Stroke Study |
| August 25 |
Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) |
| August 25 |
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes |
| August 25 |
NexBio Demonstrates DAS181 (Fludase*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue |
| August 25 |
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009 |
| August 25 |
Resverlogix Phase 1b/2a Study Meets Primary Endpoint |
| August 26 |
BioAlliance Pharma Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad |
| August 26 |
BioAlliance Pharma announces positive preliminary pivotal phase III results in herpes labialis with acyclovir Lauriad |
| August 26 |
Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study |
| August 26 |
Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress |
| August 26 |
ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09% |
| August 26 |
Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer |
| August 26 |
Hormone Therapy for Prostate Cancer Patients With Certain Heart Conditions Associated With Increased Risk of Death |
| August 26 |
Genetic Variation Associated With Poorer Response, Cardiovascular Outcomes With Use of Clopidogrel |
| August 26 |
Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products |
| August 26 |
NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting |
| August 26 |
MoxDuo IR Demonstrates Fewer Side Effects Than Percocet |
| August 26 |
Genmab Announces Positive Top-Line Results for Arzerra in Front Line NHL |
| August 26 |
Nymox's NX-1207 Shows Major Effect on Liver Cancer |
| August 26 |
New Data Published in the Journal Population Health Management Show Significant Misuse of Pain Medication Among Chronic Pain Population |
| August 27 |
Medgenics, Inc. Announces Patient Nearing Unprecedented 11 Months of Anemia Relief in Clinical Trial From Single Treatment of Biopump Tissue Technology; News Follows Significant Interest of Strategic Partner for New Application |
| August 27 |
UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus |
| August 28 |
Forest Laboratories, Inc. and Nycomed Announce a Conference Call to Review Publication of Daxas Phase III Clinical Trial Results |
| August 28 |
Four Studies Published in The Lancet Show Roflumilast (Daxas), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations |
| August 28 |
Blood Thinner Causes Stroke in Some Dialysis Patients |
| August 28 |
Nycomed/Forest - Ph III Data Published in The Lancet Showing that Roflumilast (Daxas), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations |
| August 28 |
Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009 |
| August 28 |
BioAlliance Pharma to present at the French-Norwegian Interdisciplinary Symposium on Nano and Micro Frontiers in Biology and Medicine (Bergen, Norway, August 31 to September 2, 2009) |
| August 31 |
Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes |
| August 31 |
Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients |
